Meticulous Research®—leading global market research company published a research report titled, ‘NGS Automation Market By Product (Platform, Consumables), Sequencing Type (Whole Genome, Exome, Targeted), Application (Drug Discovery, Diagnostics), End User (Hospitals, Diagnostic Laboratories, Pharmaceutical, Academic) - Global Forecast to 2029’
According to this latest publication from Meticulous Research®, the NGS automation market is expected to grow at a CAGR of 13.4% from 2022 to reach $1.33 billion by 2029. The growth of this market is attributed to factors such as the increasing demand for automation in NGS workflow, the rising incidences of cancer, and the increasing R&D investments and healthcare expenditure.
In addition, the increasing applications of next-generation sequencing and the rising number of collaborations between companies to develop library preparation protocols are expected to provide significant growth opportunities for this market.
However, the high cost of automation workstations is expected to restrain the growth of this market to a notable extent. In addition, factors such as regulatory & standardization concerns in diagnostic testing and the requirement of high-skilled personnel for operating automation software are the major challenges for the growth of this market.
NGS Automation Market: Future Outlook
The NGS automation market is segmented based on product, application, sequencing type, end user, and geography. The study also evaluates industry competitors and analyzes the market at the country level.
Based on product, in 2022, the workstation/robotic platform segment is estimated to account for the largest share of this market. The large share of this segment is attributed to factors such as the increasing demand for the automation of NGS workflow, the rising adoption of automation workstations/robotic platforms by pharmaceutical and biotechnology companies and in diagnostic laboratories, and the increasing number of funding by governments for drug discovery and research.
Based on application, in 2022, the drug discovery segment is estimated to account for the largest share of this market. The large share of this segment is attributed to the increasing utilization of NGS for identifying novel drug targets and developing therapeutic techniques that target specific genes and proteins, such as targeted therapies, gene therapies, and oligonucleotide therapies, resulting in the increased demand for automation of NGS workflow.
Based on sequencing type, in 2022, the whole genome sequencing segment is estimated to account for the largest share of this market. The large share of this segment is attributed to the advantages of whole-genome sequencing (WGS) in discovery applications, such as identifying causative variants and novel genome assembly, and the ability of this method to detect single nucleotide variants, insertions/deletions, copy number changes, and large structural variants. In addition, the increasing application of WGS in cancer diagnosis and targeted therapy in precision oncology drives the demand for NGS automation in whole-genome sequencing.
In 2022, based on end user, the pharmaceutical and biotechnology companies segment is estimated to account for the largest share of the market. The large share of this segment is attributed to the rising R&D expenditure and the growing demand for new drug discoveries using advanced technologies. Additionally, the financial capability of these companies to invest in NGS automation workstations and acquire trained personnel contributes to the growth of the pharmaceutical and biotechnology companies segment.
This research report analyzes major geographies and provides a comprehensive analysis of North America (U.S., Canada), Europe (Germany, France, U.K., Italy, Spain, and RoE), Asia-Pacific (Japan, China, India, and RoAPAC), Latin America, and the Middle East & Africa.
In 2022, North America is estimated to account for the largest share of the NGS automation market, followed by Europe and Asia-Pacific. North America’s major market is attributed to the rising demand for NGS automation among researchers and scientists, the governments’ increasing support and investments to enhance genome sequencing infrastructure in the region, and the growing number of R&D investments by pharmaceutical and biopharmaceutical companies.
Download Sample Report Here: https://www.meticulousresearch.com/download-sample-report/cp_id=5271
The key players operating in the NGS automation market are Agilent Technologies, Inc. (U.S.), Danaher Corporation (U.S.), Eppendorf AG (Germany), Hamilton Company (U.S.), PerkinElmer, Inc. (U.S.), Tecan Group Ltd. (Switzerland), PRIMADAG SAS (France), BRAND GMBH + CO KG (Germany), Hudson Robotics (U.S.), SPT Labtech (U.K.), Thermo Fisher Scientific Inc. (U.S.), and F. Hoffmann-La Roche AG (Switzerland).
Key questions answered in the report-
Contact Sales- +1-646-781-8004
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Dental Practice Management Software Market Worth $ 3.11 Billion by 2029Read More
Indonesia In Vitro Diagnostics Market to be Worth $1.11 Billion by 2029Read More